Latest Breaking News On - பால் பெர்கர் - Page 4 : comparemela.com

Share this article Share this article SAN FRANCISCO, March 12, 2021 /PRNewswire/  Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, announced that apremilast (Otezla), made by Amgen, has been dropped for futility. Apremilast was chosen for testing in the I-SPY COVID Trial because it is a phosphodiesterase-4 (PDE4) inhibitor hypothesized to blunt the cytokine storm that accompanies critical illness associated with COVID-19. The I-SPY COVID Trial is a phase II, open label, adaptive platform trial being conducted in critically ill COVID-19 patients who are receiving high flow oxygen or mechanical ventilation. The trial was designed to rapidly screen agents to find those with the best chance of reducing time to recovery (defined as reduction in oxygen demand) by approximately 50% and reducing risk of death. The I-SPY COVID Trial identified the initial agents for the study through a unique partnership with the COVID R&D Alliance, and apremilast was t

United statesNorth carolinaWinston salemSouth dakotaSan franciscoKarl thomasLaura essermanPaul bergerUniversity of californiaCarol franc buck breast care centerWake forest university winston salemDrug administrationData monitoring committeeSanford healthCovid rd allianceQuantum leap healthcare collaborative